China chip stocks rally on self-reliance bets, Nvidia scrutiny
Robert Iannone, Executive Vice President and Global Head of R&D and Chief Medical (TASE:BLWV) Officer at Jazz Pharmaceuticals (NASDAQ:JAZZ), recently sold shares in the company worth approximately $981,297. The transactions took place on March 7, 2025, and involved the sale of 7,080 ordinary shares at prices ranging from $138.21 to $140.00 per share.
The sales were conducted under a Rule 10b5-1 trading plan, a pre-established arrangement that allows insiders to sell a predetermined number of shares at predetermined times. Following these transactions, Iannone now holds 82,024 shares in the company. For deeper insights into Jazz Pharmaceuticals’ valuation and financial metrics, check out the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
Additionally, on March 5, 2025, 5,239 shares were disposed of to satisfy tax obligations related to the vesting of previously granted restricted stock units, totaling $727,959 at a price of $138.95 per share.
In other recent news, Jazz Pharmaceuticals reported its fourth-quarter 2024 earnings, exceeding analyst expectations with an earnings per share (EPS) of $6.60, compared to the forecasted $5.79. The company’s revenue for the quarter reached $1.1 billion, surpassing the anticipated $1.06 billion. Additionally, Jazz Pharmaceuticals announced its intention to acquire Chimerix (NASDAQ:CMRX) in a cash transaction valued at $935 million, expected to be completed in the second quarter of 2025. This acquisition is strategically timed ahead of a priority review for dordaviprone, a promising therapeutic for a rare form of brain cancer.
Analysts have responded to these developments with varied outlooks. UBS upgraded Jazz Pharmaceuticals to a Buy rating, setting a new price target of $179, citing confidence in the company’s base business and the potential of its Ziihera pipeline. Truist Securities also reiterated a Buy rating, raising the price target to $230, reflecting optimism about the Chimerix acquisition and the potential of dordaviprone. Meanwhile, RBC Capital Markets adjusted its price target slightly lower to $178, maintaining an Outperform rating but expressing caution due to pipeline and leadership uncertainties.
Other notable updates include Jazz Pharmaceuticals’ financial guidance for 2025, projecting revenue growth of 5%, reaching between $4.15 billion and $4.4 billion. The company also highlighted the durability of its sleep franchise and the extended market exclusivity of Epidiolex into the late 2030s. Needham raised its price target to $210, reflecting optimism about these developments and the company’s strategic focus.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.